DGAP-Adhoc

4SC AG: 4SC´s cancer compound resminostat meets primary endpoint in Phase II trial in advanced liver cancer (HCC) ahead of schedule - Seite 3

3
of which with progressive disease (PD): 6  
Progression-free survival rate after 12 weeks PFSR (=PFS/EP): 10/15= 33,3%

*Patients who withdrew from the study before their tumour status was
determined radiologically after 12 weeks - and for whom an evaluation of
tumour progression or stabilisation was therefore not possible - have not
been included in the evaluable patient population (EP). Of the nine
patients listed as drop-outs most left the study for personal reasons (i.e.
withdrawal of consent), all of them without an observed tumour progression.
Early withdrawal because of side effects was a rare occurrence and only
partly attributable to the study medication.

Adhoc Ends

---

Information and Explaination of the Issuer to this News:

Conference Call and Webcast

4SC will host a conference call and webcast on 19 January 2012 at 3pm CET
(9am EST) to inform about the data of the SHELTER study. Access to the
presentation slides can be obtained at:
http://4sc190112-live.cyber-presentation.de. Participants can access the
conference (conference ID: 4507526) under the following telephone numbers:

0800 10 12 072 (Germany)
0800 358 0886 (UK)
[phone] (USA)
[phone] (other countries)

Details of the Presentation:

Presentation No / Abstract No: C26 / 262
Title: Investigation of the HDAC inhibitor resminostat in patients with
sorafenib-resistant hepatocellular carcinoma (HCC): Clinical data from the
phase I/II SHELTER study
Session date, time and location: Friday, 20 January 2012, 11.45 am
Californian time (PST), General Poster Session B: Cancers of the Pancreas,
Small Bowel, and Hepatobiliary Tract, Moscone West Building, 2012
Gastrointestinal Cancer Symposium, San Francisco, California
Presenters: M. Bitzer, M. Horger, T. Ganten, J. Siveke, M.A. Woerns, M.M.
Dollinger, V. Zagonel, U. Cillo, G. Gerken, M.E. Scheulen, H. Wege, E.
Giannini, V. Montesarchio, F. Trevisani, A. Mais, R. Jankowsky, B. Hauns,
B. Hentsch, U.M. Lauer

Increasing clinical relevance of epigenetically induced tumour cell
resensitisation

The now presented data of the SHELTER study validate in the view of the
company impressively the growing applicability of the new epigenetic
mechanism of action offered by 4SC´s lead anti-cancer compound resminostat.
Tumour cell resensitisation, which is mediated by resminostat through the
inhibition of HDAC enzymes, is highly relevant for clinical practice, since
the supplementary administration of resminostat can permit the continued
and effective treatment of patients with a cancer drug to which patient